EANS-News: DxS and Epigenomics Cross-License Technology for In Vitro Diagnostics

Both companies to use Scorpions® technology for diagnostic products
based on DNA methylation

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

companies/cooperations/Molecular diagnostics

Press Release, Manchester, UK, and Berlin, Germany, July 20, 2009
(euro adhoc) - DxS Ltd. (Manchester, UK) and Epigenomics AG
(Frankfurt, Prime Standard: ECX) today announced that they have
cross-licensed certain technologies enabling both companies to
develop and commercialise in vitro diagnostic (IVD) products based on
DNA methylation that utilise DxS' proprietary Scorpions technology.

The cross-licensing follows a strategic agreement signed by both
companies in January 2008. Under the terms of this agreement,
Epigenomics had obtained worldwide non-exclusive rights to DxS'
Scorpions technology for R&D use and research kits, as well as an
option to expand the license to the in vitro diagnostics field. In
return, DxS received an option for a worldwide non- exclusive
research and IVD license to certain Epigenomics IP covering the use
of Scorpions technology for DNA methylation applications. Both
companies have now executed their options as granted in last years
agreement and have acquired the right to sub-license the respective
licensed technologies. Both Epigenomics and DxS have acquired the
right to sub-license the respective technologies

Dr Stephen Little, CEO of DxS, explained the unique properties of
DxS' standalone technology: "Our Scorpions technology is ideally
suited for IVD applications using real-time PCR instrumentation. The
probes are highly sensitive, sequence-specific molecules containing a
PCR primer covalently linked to a probe. Scorpion probes can provide
strong fluorescent signals, excellent sequence discrimination, short
reaction times, and predictable probe design. We believe that this
technology is ideal for DNA methylation-based IVD products,
particularly in oncology."

"With Scorpions technology we have complemented our broad technology
portfolio for DNA methylation analysis. This expands our area of
freedom to operate and give us maximum flexibility in the final
product design and testing platforms for cancer molecular diagnostic
products directly commercialised by ourselves as well as by our
partners", commented Geert Nygaard, Chief Executive Officer of
Epigenomics.

Financial terms of the agreement were not disclosed.

About DxS

DxS is a personalised medicine company providing molecular
diagnostics to aid doctors and drug companies in selecting therapies
for patients. Working in partnership with pharmaceutical companies to
support the development and sales of targeted cancer therapies by
providing biomarkers and companion diagnostics.

DxS has a continually expanding portfolio of cancer mutation
products. The TheraScreen® range of CE-marked clinical diagnostic
kits can identify genetic tumour mutations that affect how patients
respond to cancer therapies, thus enabling doctors to provide the
most beneficial treatment. DxS produces two clinical diagnostic kits,
K-RAS and EGFR29.

The TheraScreen: K-RAS Mutation kit is a companion diagnostic for
Vectibix® (Amgen) and Erbitux® (Merck KGaA) for the treatment of
colorectal cancer. DxS has an exclusive global distribution agreement
with Roche Diagnostics for the distribution of the TheraScreen: K-RAS
and TheraScreen: EGFR29 Mutation kits.

DxS' pioneering real-time PCR technology Scorpions® is highly
regarded for its proven speed and sensitivity, and is combined with
ARMS (allele specific PCR) to develop each unique DxS product. This
class-leading technology is also available for license to diagnostic
companies, for research, or for other varied applications.

DxS is a private, venture capital-backed company operating from the
heart of Manchester's Technology Quarter in the UK.

For further information please visit www.dxsdiagnostics.com

About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests in development aim at diagnosing
cancer at an early stage before symptoms occur and thereby may reduce
mortality from this dreaded disease.

Epigenomics' product pipeline contains a validated biomarker for the
early detection of colorectal cancer in blood plasma, and further
proprietary DNA methylation biomarkers at various stages of
development for prostate and lung cancer detection in urine, blood
and bronchial lavage specimens. Epigenomics' biomarker mSEPT9 for the
early detection of colorectal cancer in a simple blood sample has
demonstrated continuously highest performance in multiple clinical
studies with in total more than 3,000 individuals tested. A large
prospective clinical study - PRESEPT - for evaluation of mSEPT9 in a
screening population is currently under way (www.presept.net).

For development and global commercialization of in vitro diagnostic
test products, Epigenomics pursues a non-exclusive partnering
strategy. Strategic diagnostics industry partners include Abbott
Molecular, Philips, Sysmex Corporation and Quest Diagnostics
Incorporated, for diagnostics test products and services, and QIAGEN
N.V. for sample preparation solutions and research products.

Partners in the health care industry and the biomedical research
community can access Epigenomics' portfolio of proprietary DNA
methylation technologies and biomarkers protected by more than 150
patent families through research products, Biomarker Services, IVD
Development Collaborations, and Licensing. The company is
headquartered in Berlin, Germany, and has a wholly owned subsidiary
in Seattle, WA, U.S.A. For more information, please visit
Epigenomics' website at www.epigenomics.com.

DxS' Disclaimer. This news release contains forward-looking
statements based on current assumptions and forecasts made by DxS
Limited. The company assumes no liability whatsoever to update these
forward-looking statements or to conform them to future events or
developments.

Epigenomics' Disclaimer. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG
and its business. Such statements involve certain known and unknown
risks, uncertainties and other factors which could cause the actual
results, financial condition, performance or achievements of
Epigenomics AG to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

Contacts:

For further information on DxS, please contact:

Sue Charles, Tony Stephenson, Dr John McIntyre
College Hill Life Sciences
+44 (0)20 7866 7864
DxS@collegehill.com

For further Information on Epigenomics, please contact:

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
+49 30 24345 368
pr@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade